An update on serum amyloid A–LDL and its potential use for dyslipidemic patients receiving lipid-modulating treatment

References

• Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low‑density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320(14), 915–924 (1989).
   Google Scholar
• Steinberg D, Witztum JL. Oxidized lowdensity lipoprotein and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 30(12), 2311–2316 (2010).
   Google Scholar
• Sangle GV, Shen GX. Signaling mechanisms for oxidized LDL‑induced oxidative stress and the upregulation of plasminogen activator inhibitor‑1 in vascular cells. Clin. Lipidol. 5(2), 221–232 (2010).
   Google Scholar
• Itabe H, Ueda M. Measurement of plasma oxidized low‑density lipoprotein and its clinical implications. J. Atheroscler. Thromb. 14(1), 1–11 (2007).
   Google Scholar
• Zakynthinos E, Pappa N. Inflammatory biomarkers in coronary artery disease. J. Cardiol. 53(3), 317–333 (2009).
   Google Scholar
• Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ. J. 74(2), 213–220 (2010).
   Google Scholar
• Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin. Chem. Lab. Med. 37(4), 381–388 (1999).
   Google Scholar
• King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr. Opin. Lipidol. 22(4), 302–307 (2011).
   Google Scholar
• Abe‑Dohmae S, Kato KH, Kumon Y et al. Serum amyloid A generates high density lipoprotein with cellular lipid in an ABCA1‑or ABCA7‑dependent manner. J. Lipid. Res. 47(7), 1542–1250 (2006).
   Google Scholar
• Ogasawara K, Mashiba S, Wada Y et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 174(2), 349–356 (2004); erratum in: Atherosclerosis 176(2), 431 (2004). ▪ Demonstrates serum amyloid A–LDL (SAA–LDL) to be a predictor of cardiac events in patients with coronary artery disease.
   Google Scholar
• Kotani K, Satoh N, Yamada T, Gugliucci A. The potential of serum amyloid A–LDL as a novel biomarker for cardiovascular disease risk. Clin. Lipidol. 5(4), 489–495 (2010). ▪ Demonstrates the overview of the method to measure the SAA–LDL level and the clinical association between SAA–LDL and atherosclerotic risk factors.
   Google Scholar
• Kotani K, Satoh‑Asahara N, Kato Y et al. Japan obesity and metabolic syndrome study group: serum amyloid A low‑density lipoprotein levels and smoking status in obese Japanese patients. J. Int. Med. Res. 39(5), 1917–1922 (2011).
   Google Scholar
• Kotani K, Satoh N, Kato Y et al. Japan obesity and metabolic syndrome study group: a novel oxidized low‑density lipoprotein marker, serum amyloid A–LDL, is associated with obesity and the metabolic syndrome. Atherosclerosis 204(2), 526–531 (2009). ▪ Demonstrates the clinical significance of SAA–LDL in patients with obesity and metabolic syndrome.
   Google Scholar
• Kotani K, Asahara‑Satoh N, Kato Y et al. Japan obesity and metabolic syndrome study (JOMS) group: remnant‑like particle cholesterol and serum amyloid A‑low‑density lipoprotein levels in obese subjects with metabolic syndrome. J. Clin. Lipidol. 5(5), 395–400 (2011).
   Google Scholar
• Kotani K, Koibuchi H, Yamada T, Taniguchi N. The effects of lifestyle modification on a new oxidized low‑density lipoprotein marker, Serum amyloid A–LDL, in subjects with primary lipid disorder. Clin. Chim. Acta 409(1–2), 67–69 (2009).
   Google Scholar
• Satoh N, Shimatsu A, Kotani K et al. Highly purified eicosapentaenoic acid reduces cardio–ankle vascular index in association with decreased Serum amyloid A–LDL in metabolic syndrome. Hypertens. Res. 32(11), 1004–1008 (2009). ▪ Demonstrates the effects of eicosapentaenoic acid on the SAA–LDL level in association with the arterial stiffness index.
   Google Scholar
• Kotani K, Satoh N, Yamada T. Bezafibrate and serum amyloid A‑low‑density lipoprotein complex in patients with Type 2 diabetes mellitus and hypertriglyceridemia. Eur. J. Intern. Med. 21(2), e10 (2010).
   Google Scholar
• Ueno H, Saitoh Y, Mizuta M et al. Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. Obes. Res. Clin. Pract. 5(4), 335–340 (2011). ▪ Demonstrates the effects of fenofibrate on the SAA–LDL level.
   Google Scholar
• Kotani K, Yamada T, Miyamoto M, Ishibashi S, Taniguchi N, Gugliucci A. Influence of atorvastatin on serum amyloid A‑low density lipoprotein complex in hypercholesterolemic patients. Pharmacol. Rep. 64(1), 212–216 (2012). ▪ Demonstrates the effects of statins on the SAA–LDL level.
   Google Scholar
• Satoh N, Shimatsu A, Kotani K et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C‑reactive protein in metabolic syndrome. Diabetes Care 30(1), 144–146 (2007).
   Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M et al. Japan EPA Lipid Intervention Study (JELIS) Investigators: effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‑label, blinded endpoint analysis. Lancet 369(9567), 1090–1098 (2007); erratum in: Lancet 370(9583), 220 (2007).
   Google Scholar
• Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between w‑3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta‑analysis. JAMA 308(10), 1024–1033 (2012).
   Google Scholar
• Chowdhury R, Stevens S, Gorman D et al. Association between fish consumption, long chain w 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta‑analysis. BMJ 345, e6698 (2012).
   Google Scholar
• Nikfardjam M. w‑3 fatty acids and cardioprotection – IIb or not IIb? Lancet 380(9858), 1976–1977 (2012).
   Google Scholar
• Kotani K, Miyamoto M, Taniguchi N. Clinical significance of the cardio–ankle vascular index (CAVI) in hypertension. Curr. Hypertens. Rev. 6(4), 251–253 (2010).
   Google Scholar
• Katsiki N, Nikolic D, Montalto G, Banach M, Mikhailidis DP, Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des. 19(17), 3124–3131 (2013).
   Google Scholar
• Tesone PA, Gladstein J, Acuña AM. Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia. Curr. Med. Res. Opin. 9(9), 650–657 (1985).
   Google Scholar
• Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL cholesterol lowering. Am. J. Cardiovasc. Drugs 10(Suppl. 1), S10–S17 (2010).
   Google Scholar
• Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as antiinflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 18(11), 1519–1530 (2012).
   Google Scholar
• Yamada S, Gotoh T, Nakashima Y et al. Distribution of serum C‑reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi medical school cohort study. Am. J. Epidemiol. 153(12), 1183–1190 (2001).
   Google Scholar
• Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr. Opin. Lipidol. 21(4), 298–304 (2010).
   Google Scholar
• da Silva PM. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin. Am. J. Cardiovasc. Drugs 11(2), 93–107 (2011).
   Google Scholar
• Chapman MJ, Kastelein JJP. Pitavastatin: a new option for the reduction of cardiovascular risk factors. Clin. Lipidol. 7(3 Suppl. 1), S1 (2012).
   Google Scholar
• Chapman MJ. Pitavastatin: novel effects on lipid parameters. Atheroscler. Suppl. 12(3), 277–284 (2011).
   Google Scholar
• Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 8, 415–427 (2012).
   Google Scholar
• Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP. Ezetimibe therapy for dyslipidemia: an update. Curr. Pharm. Des. 19(17), 3107–3114 (2013).
   Google Scholar
• Kurobe H, Aihara K, Higashida M et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J. Atheroscler. Thromb. 18(12), 1080–1189 (2011).
   Google Scholar